{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T05:29:19Z","timestamp":1780637359684,"version":"3.54.1"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"24","license":[{"start":{"date-parts":[[2015,7,26]],"date-time":"2015-07-26T00:00:00Z","timestamp":1437868800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Anal Bioanal Chem"],"published-print":{"date-parts":[[2015,9]]},"DOI":"10.1007\/s00216-015-8915-8","type":"journal-article","created":{"date-parts":[[2015,7,25]],"date-time":"2015-07-25T01:28:24Z","timestamp":1437787704000},"page":"7477-7485","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Surface plasmon resonance-based methodology for anti-adalimumab antibody identification and kinetic characterization"],"prefix":"10.1007","volume":"407","author":[{"given":"Feliciana","family":"Real-Fern\u00e1ndez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rolando","family":"Cimaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giada","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Simonini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Giani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"Pagnini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Maria","family":"Papini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Rovero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,7,26]]},"reference":[{"key":"8915_CR1","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/S1568-9972(03)00048-X","volume":"2","author":"AG Suryaprasad","year":"2003","unstructured":"Suryaprasad AG, Prindiville T (2003) The biology of TNF blockade. Autoimmun Rev 2:346\u2013357","journal-title":"Autoimmun Rev"},{"issue":"1 Suppl","key":"8915_CR2","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1177\/03946320140270S102","volume":"27","author":"A Armuzzi","year":"2014","unstructured":"Armuzzi A, Lionetti P, Blandizzi C, Caporali R, Chimenti S, Cimino L, Gionchetti P, Girolomoni G, Lapadula G, Marchesoni A, Marcellusi A, Mennini FS, Salvarani C, Cimaz R (2014) Anti-TNF agents as therapeutic choice in immune-mediated inflammatory diseases: focus on adalimumab. Int J Immunopathol Pharmacol 27(1 Suppl):11\u201332","journal-title":"Int J Immunopathol Pharmacol"},{"issue":"6","key":"8915_CR3","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.semarthrit.2012.10.006","volume":"42","author":"WJ Ungar","year":"2013","unstructured":"Ungar WJ, Costa V, Burnett HF, Feldman BM, Laxer RM (2013) The use of biologic response modifiers in polyarticular-course juvenile idiopathic arthritis: a systematic review. Semin Arthritis Rheum 42(6):597\u2013618","journal-title":"Semin Arthritis Rheum"},{"issue":"11","key":"8915_CR4","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1136\/annrheumdis-2012-201991","volume":"72","author":"MH Otten","year":"2013","unstructured":"Otten MH, Anink J, Spronk S, van Suijlekom-Smit LW (2013) Efficacy of biological agents in juvenile idiopathic arthritis: a systematic review using indirect comparisons. Ann Rheum Dis 72(11):1806\u201312","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"8915_CR5","doi-asserted-by":"crossref","first-page":"2580","DOI":"10.1002\/art.38741","volume":"66","author":"H Schmeling","year":"2014","unstructured":"Schmeling H, Minden K, Foeldvari I, Ganser G, Hospach T, Horneff G (2014) Efficacy and safety of adalimumab as the first and second biologic agent in juvenile idiopathic arthritis: the German biologics JIA registry. Arthritis Rheumatol 66(9):2580\u20132589","journal-title":"Arthritis Rheumatol"},{"key":"8915_CR6","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1186\/1756-0500-7-316","volume":"7","author":"F Torre La","year":"2014","unstructured":"La Torre F, Cattalini M, Teruzzi B, Meini A, Moramarco F, Iannone F (2014) Efficacy of adalimumab in young children with juvenile idiopathic arthritis and chronic uveitis: a case series. BMC Res Notes 7:316","journal-title":"BMC Res Notes"},{"issue":"8","key":"8915_CR7","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa0706290","volume":"359","author":"DJ Lovell","year":"2008","unstructured":"Lovell DJ, Ruperto N, Goodman S, Reiff A, Jung L, Jarosova K, Nemcova D, Mouy R, Sandborg C, Bohnsack J, Elewaut D, Foeldvari I, Gerloni V, Rovensky J, Minden K, Vehe RK, Weiner LW, Horneff G, Huppertz HI, Olson NY, Medich JR, Carcereri-De-Prati R, McIlraith MJ, Giannini EH, Martini A (2008) Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl J Med 359(8):810\u2013820","journal-title":"N Engl J Med"},{"issue":"9","key":"8915_CR8","first-page":"S57","volume":"41","author":"J Salfeld","year":"1998","unstructured":"Salfeld J, Kaymakcalan Z, Tracey D, Roberts A, Kamen R (1998) Generation of fully human anti-TNF antibody D2E7 [abstract]. Arthritis Rheum 41(9):S57","journal-title":"Arthritis Rheum"},{"issue":"12","key":"8915_CR9","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1136\/annrheumdis-2014-205554","volume":"73","author":"EH Vogelzang","year":"2014","unstructured":"Vogelzang EH, Kneepkens EL, Nurmohamed MT, van Kuijk AW, Rispens T, Wolbink G, Krieckaert CL (2014) Anti-adalimumab antibodies and adalimumab concentrations in psoriatic arthritis: an association with disease activity at 28 and 52 weeks of follow-up. Ann Rheum Dis 73(12):2178\u20132182","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"8915_CR10","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1007\/s00535-013-0803-4","volume":"49","author":"H Imaeda","year":"2014","unstructured":"Imaeda H, Takahashi K, Fujimoto T, Bamba S, Tsujikawa T, Sasaki M, Fujiyama Y, Andoh A (2014) Clinical utility of newly developed immunoassays for serum concentrations of adalimumab and anti-adalimumab antibodies in patients with Crohn\u2019s disease. J Gastroenterol 49(1):100\u2013109","journal-title":"J Gastroenterol"},{"issue":"3","key":"8915_CR11","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1136\/ard.2009.108787","volume":"69","author":"AW vanKuijk","year":"2010","unstructured":"vanKuijk AW, de Groot M, Stapel SO, Dijkmans BA, Wolbink GJ, Tak PP (2010) Relationship between the clinical response to adalimumab treatment and serum levels of adalimumab and anti-adalimumab antibodies in patients with psoriatic arthritis. Ann Rheum Dis 69(3):624\u2013625, 13","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"8915_CR12","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1136\/ard.2006.065615","volume":"66","author":"GM Bartelds","year":"2007","unstructured":"Bartelds GM, Wijbrandts CA, Nurmohamed MT, Stapel S, Lems WF, Aarden L, Dijkmans BA, Tak PP, Wolbink GJ (2007) Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann Rheum Dis 66(7):921\u2013926","journal-title":"Ann Rheum Dis"},{"key":"8915_CR13","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1136\/annrheumdis-2012-202545","volume":"72","author":"FB Vincent","year":"2013","unstructured":"Vincent FB, Morand EF, Murphy K, Mackay F, Mariette X, Marcelli C (2013) Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralizing agents in chronic inflammatory diseases: a real issue, a clinical perspective. Ann Rheum Dis 72:165\u2013178","journal-title":"Ann Rheum Dis"},{"key":"8915_CR14","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jim.2015.01.007","volume":"418","author":"K Bloem","year":"2015","unstructured":"Bloem K, van Leeuwen A, Verbeek G, Nurmohamed MT, Wolbink GJ, van der Kleij D, Rispens T (2015) Systematic comparison of drug-tolerant assays for anti-drug antibodies in a cohort of adalimumab-treated rheumatoid arthritis patients. J Immunol Methods 418:29\u201338","journal-title":"J Immunol Methods"},{"issue":"14","key":"8915_CR15","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1001\/jama.2011.406","volume":"305","author":"GM Bartelds","year":"2011","unstructured":"Bartelds GM, Krieckaert CLM, Nurmohamed MT, van Schouwenburg PA, Lems WF, Twisk JWR, Dijkmans BAC, Aarden L, Wolbink GJ (2011) Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long term follow-up. JAMA 305(14):1460\u20131468","journal-title":"JAMA"},{"key":"8915_CR16","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1136\/annrheumdis-2012-201445","volume":"72","author":"PA Schouwenburg van","year":"2013","unstructured":"van Schouwenburg PA, van de Stadt LA, de Jong RN, van Buren EEL, Kruithof S, de Groot E, Hart M, van Ham SM, Rispens T, Aarden L, Wolbink GJ, Wouters D (2013) Adalimumab elicits a restricted anti-idiotypic antibody response in autoimmune patients resulting in functional neutralization. Ann Rheum Dis 72:104\u2013109","journal-title":"Ann Rheum Dis"},{"key":"8915_CR17","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1136\/annrheumdis-2014-206237","volume":"74","author":"KA vanSchie","year":"2015","unstructured":"vanSchie KA, Hart MH, de Groot ER, Kruithof S, Aarden LA, Wolbink GJ, Rispens T (2015) The antibody response against human and chimeric anti-TNF therapeutic antibodies primarily targets the TNF binding region. Ann Rheum Dis 74:311\u2013314","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"8915_CR18","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.coi.2008.06.011","volume":"20","author":"L Aarden","year":"2008","unstructured":"Aarden L, Ruuls SR, Wolbink G (2008) Immunogenicity of anti-tumor necrosis factorantibodies-toward improved methods of anti-antibody measurement. Curr Opin Immunol 20(4):431\u2013435","journal-title":"Curr Opin Immunol"},{"key":"8915_CR19","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.jim.2005.06.014","volume":"304","author":"A Patton","year":"2005","unstructured":"Patton A, Mullenix MC, Swanson SJ, Koren E (2005) An acid dissociation bridging ELISA for detection of antibodies directed against therapeutic proteins in the presence of antigen. J Immunol Methods 304:189\u2013195","journal-title":"J Immunol Methods"},{"issue":"1\u20132","key":"8915_CR20","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.jim.2010.09.005","volume":"362","author":"PA Schouwenburg van","year":"2010","unstructured":"van Schouwenburg PA, Bartelds GM, Hart MH, Aarden L, Wolbink GJ, Wouters D (2010) A novel method for the detection of antibodies to adalimumab in the presence of drug reveals \u201chidden\u201d immunogenicity in rheumatoid arthritis patients. J Immunol Methods 362(1\u20132):82\u201388","journal-title":"J Immunol Methods"},{"key":"8915_CR21","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1136\/annrheumdis-2012-202407","volume":"72","author":"PA vanSchouwenburg","year":"2013","unstructured":"vanSchouwenburg PA, Krieckaert CL, Rispens T, Aarden L, Wolbink GJ, Wouters D (2013) Long-term measurement of anti-adalimumab using pH-shift-anti-idiotype antigen binding test shows predictive value and transient antibody formation. Ann Rheum Dis 72:1680\u20131686","journal-title":"Ann Rheum Dis"},{"key":"8915_CR22","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jpba.2013.01.031","volume":"78\u201379","author":"SL Wang","year":"2013","unstructured":"Wang SL, Hauenstein S, Ohrmund L, Shringarpure R, Salbato J, Reddy R, McCowen K, Shah S, Lockton S, Chuang E, Singh S (2013) Monitoring of adalimumab and antibodies-to-adalimumab levels in patient serum by the homogeneous mobility shift assay. J Pharm Biomed Anal 78\u201379:39\u201344","journal-title":"J Pharm Biomed Anal"},{"key":"8915_CR23","doi-asserted-by":"crossref","first-page":"7467","DOI":"10.4049\/jimmunol.178.11.7467","volume":"178","author":"JA Lofgren","year":"2007","unstructured":"Lofgren JA, Dhandapani S, Pennucci JJ, Abbott CM, Mytych DT, Kaliyaperumal A, Swanson SJ, Mullenix MC (2007) Comparing ELISA and surface plasmon resonante for assesing clinical immunogenicity of panitumumab. J Immunol 178:7467\u20137472","journal-title":"J Immunol"},{"key":"8915_CR24","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.ab.2009.04.021","volume":"390","author":"K Stubenrauch","year":"2009","unstructured":"Stubenrauch K, Wessels U, Vogel R, Schleypen J (2009) Evaluation of a biosensor immunoassay for simultaneous characterization of isotype and binding region of human antitocilizumab antibodies with control surrogate standards. Anal Biochem 390:189\u2013196","journal-title":"Anal Biochem"},{"key":"8915_CR25","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.jim.2013.07.010","volume":"396","author":"DK Weeraratne","year":"2013","unstructured":"Weeraratne DK, Lofgren J, Dinnogen S, Swanson SJ, Zhong ZD (2013) Development of a biosensor-based immunogenicity assay capable of blocking soluble drug target interference. J Immunol Methods 396:44\u201355","journal-title":"J Immunol Methods"},{"key":"8915_CR26","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.clim.2009.01.002","volume":"131","author":"Z Kaymakcalan","year":"2009","unstructured":"Kaymakcalan Z, Sakorafas P, Bose S, Scesney S, Xiong L, Hanzatian DK, Salfeld J, Sasso EH (2009) Comparisons of affinities, avidities, and complement activation of adalimumab, infliximab, and etanercept in binding to soluble and membrane tumor necrosis factor. Clin Immunol 131:308\u2013316","journal-title":"Clin Immunol"},{"issue":"3","key":"8915_CR27","doi-asserted-by":"crossref","first-page":"491","DOI":"10.4161\/mabs.24245","volume":"5","author":"T Arvinte","year":"2013","unstructured":"Arvinte T, Palais C, Green-Trexler E, Gregory S, Mach H, Narasimhan C, Shameem M (2013) Aggregation of biopharmaceuticals in human plasma and human serum. mAbs 5(3):491\u2013500","journal-title":"mAbs"},{"issue":"3","key":"8915_CR28","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1203\/PDR.0b013e318208451d","volume":"69","author":"M Kosma\u010d","year":"2011","unstructured":"Kosma\u010d M, Av\u010din T, Toplak N, Simonini G, Cimaz R, \u0160erbec VC (2011) Exploring the binding sites of anti-infliximab antibodies in pediatric patients with rheumatic diseases treated with infliximab. Pediatr Res 69(3):243\u2013248, 14","journal-title":"Pediatr Res"},{"key":"8915_CR29","author":"F Real Fern\u00e1ndez","year":"2015","unstructured":"Real Fern\u00e1ndez F, Di Pisa M, Rossi G, Auberger N, Lequin O, Larregola M, Benchohra A, Mansuy C, Chassaing G, Lolli F, Hayek J, Lavielle S, Rovero P, Mallet JM, Papini AM (2015) Antibody recognition in multiple sclerosis and Rett syndrome using a collection of linear and cyclic N-glucosylated antigenic probes. Biopolymers (Pept Sci). doi: 10.1002\/bip.22677","journal-title":"Biopolymers (Pept Sci)"},{"key":"8915_CR30","volume-title":"Immunochemistry in practice","author":"A Johnstone","year":"1988","unstructured":"Johnstone A, Thorpe (1988) Immunochemistry in practice, 3rd edn. Wiley-Blackwell, New York","edition":"3"},{"key":"8915_CR31","first-page":"117","volume-title":"The evidence base of clinical diagnosis: how to do diagnostic research","author":"JDF Habbema","year":"2002","unstructured":"Habbema JDF, Eijkmans R, Krijnen P, Knottnerus JA (2002) Analysis of data on the accuracy of diagnostic tests. In: Knottnerus JA (ed) The evidence base of clinical diagnosis: how to do diagnostic research. BMJ Books, London, pp 117\u2013143"},{"issue":"12","key":"8915_CR32","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1007\/s10067-012-2082-5","volume":"31","author":"T Imagawa","year":"2012","unstructured":"Imagawa T, Takei S, Umebayashi H, Yamaguchi K, Itoh Y, Kawai T, Iwata N, Murata T, Okafuji I, Miyoshi M, Onoe Y, Kawano Y, Kinjo N, Mori M, Mozaffarian N, Kupper H, Santra S, Patel G, Kawai S, Yokota S (2012) Efficacy, pharmacokinetics, and safety of adalimumab in pediatric patients with juvenile idiopathic arthritis in Japan. Clin Rheumatol 31(12):1713\u20131721","journal-title":"Clin Rheumatol"},{"key":"8915_CR33","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1093\/rheumatology\/keu305","volume":"53","author":"S Murias","year":"2014","unstructured":"Murias S, Alcobendas R, Pascual-Salcedo D, Remesal A, Peralta J, Merino R (2014) Antiadalimumab antibodies in pediatric rheumatology patients: a pilot experience. Rheumatology 53:2124\u20132126","journal-title":"Rheumatology"},{"key":"8915_CR34","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.ab.2013.07.019","volume":"441","author":"MDFS Barbosa","year":"2013","unstructured":"Barbosa MDFS, Gokemeijer J, Martin AD, Bush A (2013) Altering drug tolerance of surface plasmon resonance assays for the detection of anti-drug antibodies. Anal Biochem 441:174\u2013179","journal-title":"Anal Biochem"},{"key":"8915_CR35","doi-asserted-by":"crossref","first-page":"3536","DOI":"10.1021\/jm049343o","volume":"48","author":"S Cimitan","year":"2005","unstructured":"Cimitan S, Lindgren MT, Bertucci C, Danielson UH (2005) Early absorption and distribution analysis of antitumor and anti-AIDS drugs: lipid membrane and plasma protein interactions. J Med Chem 48:3536\u20133546","journal-title":"J Med Chem"},{"issue":"50","key":"8915_CR36","doi-asserted-by":"crossref","first-page":"34482","DOI":"10.1074\/jbc.M114.615500","volume":"289","author":"PA Schouwenburg van","year":"2014","unstructured":"van Schouwenburg PA, Kruithof S, Votsmeier C, van Schie K, Hart MH, de Jong RN, van Buren EEL, van Ham M, Aarden L, Wolbink G, Wouters D, Rispens T (2014) Functional analysis of the anti-adalimumab response using patient-derived monoclonal antibodies. J Biol Chem 289(50):34482\u201334488","journal-title":"J Biol Chem"}],"container-title":["Analytical and Bioanalytical Chemistry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00216-015-8915-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00216-015-8915-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00216-015-8915-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,28]],"date-time":"2019-08-28T14:21:26Z","timestamp":1567002086000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00216-015-8915-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7,26]]},"references-count":36,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2015,9]]}},"alternative-id":["8915"],"URL":"https:\/\/doi.org\/10.1007\/s00216-015-8915-8","relation":{},"ISSN":["1618-2642","1618-2650"],"issn-type":[{"value":"1618-2642","type":"print"},{"value":"1618-2650","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,7,26]]}}}